MA27380A1 - Dérivés hétérobiaryliques servant d'inhibiteurs de métalloprotéinases de matrice - Google Patents

Dérivés hétérobiaryliques servant d'inhibiteurs de métalloprotéinases de matrice

Info

Publication number
MA27380A1
MA27380A1 MA28097A MA28097A MA27380A1 MA 27380 A1 MA27380 A1 MA 27380A1 MA 28097 A MA28097 A MA 28097A MA 28097 A MA28097 A MA 28097A MA 27380 A1 MA27380 A1 MA 27380A1
Authority
MA
Morocco
Prior art keywords
matrix metalloproteinase
metalloproteinase inhibitors
derivatives used
heterobiaryl
heterobiaryl derivatives
Prior art date
Application number
MA28097A
Other languages
English (en)
Inventor
Amy Mae Bunker
Mark Anthony Morris
Patrick Michael O'brien
Michael William Wilson
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MA27380A1 publication Critical patent/MA27380A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MA28097A 2002-08-13 2005-02-11 Dérivés hétérobiaryliques servant d'inhibiteurs de métalloprotéinases de matrice MA27380A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40316202P 2002-08-13 2002-08-13

Publications (1)

Publication Number Publication Date
MA27380A1 true MA27380A1 (fr) 2005-06-01

Family

ID=31715953

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28097A MA27380A1 (fr) 2002-08-13 2005-02-11 Dérivés hétérobiaryliques servant d'inhibiteurs de métalloprotéinases de matrice

Country Status (36)

Country Link
US (2) US7179822B2 (fr)
EP (1) EP1536784A1 (fr)
JP (2) JP3889761B2 (fr)
KR (1) KR100645681B1 (fr)
CN (1) CN100379415C (fr)
AP (1) AP2005003225A0 (fr)
AR (1) AR040851A1 (fr)
AU (1) AU2003250496B2 (fr)
BR (1) BR0313464A (fr)
CA (1) CA2494067C (fr)
CR (1) CR7684A (fr)
DO (1) DOP2003000678A (fr)
EA (1) EA007721B1 (fr)
EC (1) ECSP055595A (fr)
GE (2) GEP20074021B (fr)
GT (1) GT200300171A (fr)
HK (1) HK1078770A1 (fr)
HN (1) HN2003000243A (fr)
HR (1) HRP20050137A2 (fr)
IL (1) IL166414A0 (fr)
IS (1) IS7644A (fr)
MA (1) MA27380A1 (fr)
MX (1) MXPA05001340A (fr)
NO (1) NO322624B1 (fr)
NZ (1) NZ538078A (fr)
OA (1) OA12895A (fr)
PA (1) PA8578101A1 (fr)
PE (1) PE20040864A1 (fr)
PL (1) PL375341A1 (fr)
RS (1) RS20050099A (fr)
SG (1) SG148040A1 (fr)
TN (1) TNSN05037A1 (fr)
TW (1) TWI256890B (fr)
UY (1) UY27926A1 (fr)
WO (1) WO2004014366A1 (fr)
ZA (1) ZA200501136B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2462442A1 (fr) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Inhibiteurs de metalloproteinase matricielle (mmp) a base d'alkyne
EP1394159A1 (fr) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
WO2005002585A1 (fr) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combinaison d'un inhibiteur allosterique de la metalloproteinase-13 matricielle et d'un ligand au recepteur alpha-2-delta
WO2005033079A1 (fr) * 2003-09-30 2005-04-14 Eisai Co., Ltd. Agent antifongique a compose heterocyclique
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
US20050241110A1 (en) * 2004-04-09 2005-11-03 Bruce Baker Ergonomic handles, especially for garden tools
US20090227799A1 (en) * 2004-08-09 2009-09-10 Kazutaka Nakamoto Novel Antimalarial Agent Containing Heterocyclic Compound
EP1799659A1 (fr) 2004-10-13 2007-06-27 PTC Therapeutics, Inc. Composés permettant de supprimer les effets des mutations non-sens, et méthodes d emploi desdits composés
US20080161365A1 (en) * 2004-12-08 2008-07-03 Pfizer Inc. Methylene Derivatives
US20090137637A1 (en) * 2004-12-08 2009-05-28 Pfizer Inc. Tetrazolyl-Methylene Amino Acid Derivatives
US7829585B2 (en) 2005-03-30 2010-11-09 Eisai R&D Management Co., Ltd. Antifungal agent containing pyridine derivative
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
JP5376805B2 (ja) * 2005-11-04 2013-12-25 日本碍子株式会社 ハニカム構造体及びハニカム触媒体
AU2006332694A1 (en) * 2005-12-30 2007-07-12 Alantos Pharmaceuticals, Holding, Inc. Substituted bis-amide metalloprotease inhibitors
US20080015193A1 (en) * 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
WO2008035726A1 (fr) 2006-09-21 2008-03-27 Eisai R & D Management Co., Ltd. Dérivé de pyridine substitué par un cycle hétéroaryle, et agent antifongique le comprenant
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
CN101622251B (zh) 2007-04-27 2012-07-04 卫材R&D管理有限公司 杂环取代吡啶衍生物的盐或其结晶
AU2008281509A1 (en) * 2007-08-02 2009-02-05 Pfizer Inc. Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
CA2811479A1 (fr) * 2010-09-17 2012-03-22 Purdue Pharma L.P. Composes de pyridine et ses utilisations
EP2928471B1 (fr) 2012-12-06 2020-10-14 Celgene Quanticel Research, Inc. Inhibiteurs de l'histone déméthylase
CN104496920A (zh) * 2014-12-04 2015-04-08 北京理工大学 一种n-烯丙基-二取代四唑及其制备方法和检测方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049572A (en) * 1987-04-06 1991-09-17 Riker Laboratories, Inc. Substituted di-t-butylphenols and anti-allergic use thereof
IL85896A (en) * 1987-04-06 1993-01-14 Riker Laboratories Inc Substituted di-tert.- butylphenols and pharmaceutical compositions containing them
US5425289A (en) 1993-10-21 1995-06-20 Snap-On Incorporated Bung tool
DE3931432A1 (de) 1989-09-21 1991-04-04 Hoechst Ag Pyrimidin-4,6-dicarbonsaeurediamide, verfahren zu deren herstellung sowie verwendung derselben sowie arzneimittel auf basis dieser verbindungen
US5260323A (en) 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
EP0541042A1 (fr) 1991-11-05 1993-05-12 Hoechst Aktiengesellschaft Dérivés d'acide pyridine 2,4- et 2,5-dicarboxyliques, leur procédé de préparation et leur utilisation comme médicaments
GB9405347D0 (en) * 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
CA2242416C (fr) * 1996-01-23 2006-03-21 Shionogi & Co., Ltd. Derives d'acides amines sulfones et inhibiteurs de metalloproteinases contenant ces derives
JPH10195063A (ja) * 1996-10-21 1998-07-28 Dai Ichi Seiyaku Co Ltd エチニルチアゾール誘導体
US6008243A (en) 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6172057B1 (en) * 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
JPH11199512A (ja) 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用
BR9813719A (pt) * 1998-01-09 2000-10-17 Pfizer Agentes terapêuticos
AUPP285898A0 (en) 1998-04-07 1998-04-30 Fujisawa Pharmaceutical Co., Ltd. Amido derivatives
UA59453C2 (uk) 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
HN2000000137A (es) 1999-08-12 2001-02-02 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
GB9919413D0 (en) * 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
EP1246621A4 (fr) * 1999-12-23 2004-11-24 Nitromed Inc Inhibiteurs de cyclooxygenase-2 nitroses et nitrosyles, compositions et procedes d'utilisation
US6934639B1 (en) 2000-02-25 2005-08-23 Wyeth Methods for designing agents that interact with MMP-13
EP1138680A1 (fr) 2000-03-29 2001-10-04 Pfizer Products Inc. Acides gem-substitués alpha-sulfonylamino hydroxamiques comme inhibiteurs de métalloprotease
CA2425283A1 (fr) 2000-10-26 2002-05-02 Pfizer Products Inc. Inhibiteurs de metalloproteinase spiro-pyrimidine-2,4,6-trione
OA12528A (en) 2000-10-26 2006-06-02 Pfizer Prod Inc Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
CA2433778A1 (fr) 2001-02-14 2002-08-22 William Glen Harter Derives de thieno'2,3-d pyrimidinone utilises comme inhibiteurs de metalloproteinases matricielles
PA8539301A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
DOP2002000334A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
MXPA03005870A (es) 2001-02-14 2005-02-14 Warner Lambert Co Inhibirores de benzotiadiazina de metaloproteinasas de la matriz.
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
CA2433772C (fr) 2001-02-14 2008-10-07 Warner-Lambert Company Llc Pyrimidine comme inhibiteurs de la metalloproteinase de matrice
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
PA8539401A1 (es) 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
FR2827286A1 (fr) 2001-07-11 2003-01-17 Aventis Cropscience Sa Nouveaux composes fongicides
ATE325608T1 (de) 2001-08-13 2006-06-15 Janssen Pharmaceutica Nv 2,4,5-trisubstituted thiazolyl derivative und deren antiinflammatorische wirkung
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
WO2003030902A1 (fr) * 2001-10-09 2003-04-17 Tularik Inc. Derives d'imidazole comme agents anti-inflammatoires
CA2462442A1 (fr) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Inhibiteurs de metalloproteinase matricielle (mmp) a base d'alkyne
PA8556301A1 (es) 2001-10-12 2003-09-05 Warner Lambert Co Compuestos pirimidina de anillo fusionado alquinilado
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US7057573B2 (en) * 2001-11-07 2006-06-06 Advanced Telecommuications Research Institute International Method for controlling array antenna equipped with a plurality of antenna elements, method for calculating signal to noise ratio of received signal, and method for adaptively controlling radio receiver
US6933298B2 (en) 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
AU2002249275A1 (en) 2002-03-08 2003-09-22 Warner-Lambert Company Llc Oxo azabicyclic compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
AU2002333256A1 (en) 2002-06-25 2004-01-06 Warner-Lambert Company Llc Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
EP1388341A1 (fr) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Dérivés héteroaromatiques acylamino substitués et leur utilisation en tant que medicaments
BR0313460A (pt) * 2002-08-13 2005-07-05 Warner Lambert Co Derivados de naftaleno como inibidores de metaloproteinase da matriz
AU2003249534A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
WO2004014378A1 (fr) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives de 3-isoquinolinone utilises comme inhibiteurs de metalloprotease de matrice
AU2003249539A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
AU2003250482A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
AU2003253186A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004014908A1 (fr) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Inhibiteurs de metalloproteinases heterobicycliques
AU2003250470A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
AU2003249531A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
EP1537098A1 (fr) * 2002-08-13 2005-06-08 Warner-Lambert Company LLC Derives monocycliques en tant qu'inhibiteurs de metalloproteinases matricielles
MXPA05001783A (es) * 2002-08-13 2005-04-25 Warner Lambert Co Derivados de pirimidina-2,4-diona como inhibidores de las metaloproteinasas de matriz.
WO2004014354A1 (fr) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives d'uracile fusionnes en 1,6 utilises comme inhibiteurs de metalloproteases matricielles
AU2003250465A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors
WO2004014375A2 (fr) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Inhibiteurs de metalloprotease bicycliques condenses
WO2004014389A1 (fr) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Inhibiteurs de metalloproteases matrices a base de derives de 3,4-dihydroquinoline-2-one, d'oxazine-3-one fusionnee en 5,6, et de thiazine-3-one fusionnee en 5,6
WO2004014880A1 (fr) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Derives de chromone inhibiteurs de metalloproteinase de matrice
WO2004014916A1 (fr) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Inhibiteurs bicycliques condenses de metalloproteinases de type pyrimidine
BR0313727A (pt) * 2002-08-13 2005-07-12 Warner Lambert Co Derivados de isoquinolina como inibidores de metaloproteinase da matriz
AU2003250475A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
UY27926A1 (es) 2004-03-31
PA8578101A1 (es) 2004-05-07
DOP2003000678A (es) 2004-02-15
BR0313464A (pt) 2005-07-05
AU2003250496A1 (en) 2004-02-25
CN100379415C (zh) 2008-04-09
HK1078770A1 (en) 2006-03-24
US20040048863A1 (en) 2004-03-11
GEP20074021B (en) 2007-01-10
EP1536784A1 (fr) 2005-06-08
CN1674892A (zh) 2005-09-28
OA12895A (en) 2006-10-13
SG148040A1 (en) 2008-12-31
MXPA05001340A (es) 2005-10-18
JP2006298942A (ja) 2006-11-02
IL166414A0 (en) 2006-01-15
KR100645681B1 (ko) 2006-11-15
NZ538078A (en) 2006-09-29
GEP20064021B (en) 2007-01-10
CR7684A (es) 2007-12-04
CA2494067C (fr) 2010-04-20
ZA200501136B (en) 2006-04-26
HRP20050137A2 (en) 2005-10-31
CA2494067A1 (fr) 2004-02-19
AP2005003225A0 (en) 2005-03-31
ECSP055595A (es) 2005-04-18
NO322624B1 (no) 2006-11-06
JP3889761B2 (ja) 2007-03-07
RS20050099A (en) 2007-11-15
GT200300171A (es) 2004-03-29
TNSN05037A1 (fr) 2007-05-14
WO2004014366A1 (fr) 2004-02-19
HN2003000243A (es) 2005-11-02
TWI256890B (en) 2006-06-21
AR040851A1 (es) 2005-04-20
TW200408390A (en) 2004-06-01
PL375341A1 (en) 2005-11-28
EA200500096A1 (ru) 2005-08-25
JP2006500352A (ja) 2006-01-05
US20090029995A1 (en) 2009-01-29
NO20051236L (no) 2005-04-08
KR20050042158A (ko) 2005-05-04
PE20040864A1 (es) 2004-11-25
US7179822B2 (en) 2007-02-20
EA007721B1 (ru) 2006-12-29
IS7644A (is) 2005-01-12
AU2003250496B2 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
MA27380A1 (fr) Dérivés hétérobiaryliques servant d'inhibiteurs de métalloprotéinases de matrice
ATE308544T1 (de) N-substituiete heteroaryloxy-aryl-spiro- pyrimidine-2,4,6-trion metalloproteinase inhibitoren
DE60308850D1 (de) Pyridinoylpiperidine als 5-ht1f agonisten
ATE358667T1 (de) Pyridin-derivate als matrix metalloproteinase inhibitoren
ATE304015T1 (de) Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren
DE60309366D1 (de) Hydraulische Spannvorrichtung
DE60201760D1 (de) Hydraulische Spannvorrichtung
DE60020812D1 (de) Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel
DE60013221D1 (de) Fotopolymerisierbare Zusammensetzung
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
NO20021329D0 (no) Kinaseinhibitorer som terapeutiske midler
EE200200069A (et) Metalloproteinaaside inhibiitoriteks olevad pürimidiin-3,4,6-trioonid
NO20031853D0 (no) Spiro-pyrimidin-2,4,6-trion metalloproteinase inhibitorer
ATE502923T1 (de) Amid-verbindungen
NO20016319D0 (no) VLA-4 inhibitor-forbindelser
ATE273288T1 (de) 2,3,4,5-tetrahydro-1h-(1,4)benzodiazepin-3- hydroxamsäure als matrix metalloproteinaseinhibitoren
ATE308325T1 (de) Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trion derivate als metalloproteinase inhibitoren
NO20030868L (no) N-(3,5-diklor-2-metoksyfenyl)-4-metoksy-3-piperazin-1-yl- benzensulfonamid
DE60009260D1 (de) Thiopyranderivate as mmp-inhibitoren
ITVE20010021U1 (it) "martinetto idraulico perfezionato"
IS7943A (is) Ný amínóbensófenónefnasambönd
FI20010129A0 (fi) Kaksiviiraformeri
ATE456561T1 (de) Anilin-derivate
DE50003014D1 (de) N-substituierte perhydrodiazine
ATA2252001A (de) Hydraulische spannvorrichtung